Pharmacology of biosimilar candidate drugs in rheumatology: A literature review

Acta Reumatologica Portuguesa

Volumn 39, Issue 1, 2014, Pages 19-26

  Araujo F ^a   Cordeiro, I ^b   Teixeira, F ^c   Goncalves J ^d   Fonseca, J ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b HOSPITAL GARCIA DE ORTA   (Portugal)

^c Hospital Conde de Bertiandos   (Portugal)

^d RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

Biosimilar; Etanercept; Infliximab; Pharmacody namic; Pharmacokinetic; Rituximab

Indexed keywords

ANTIRHEUMATIC AGENT; BIOSIMILAR AGENT; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

HUMAN; RHEUMATIC DISEASES;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOSIMILAR PHARMACEUTICALS; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; RHEUMATIC DISEASES;

EID: 84897519722     PISSN: 0303464X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Strand V, Singh J. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controled trials. Am J Manag Care2007;13:S237- -251.
2. MacCamish M, Woollett G. Worldwide experience with biosimilar development. mAbs 2011;3:209-217.
3. Dörner T, Strand V, Castañeda-Hernández G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013;72:322-328.
4. Revers L, Furczon E. An introduction to biologics and biosimilars. Part I: Biologics: what are they and where do they come from? Can Pharm J 2010;143:134-139.
5. European Medicines Agency. Guideline on similar biological medical products, October 2005. http://www.ema.europa.eu/ docs/en_GB/document_library/Scientific_guideline/2009/ 09/WC500003517.pdf (Accessed October 16th, 2013).
6. Reichert J. Next generation and biosimilar monoclonal antibodies. Essential considerations towards regulatory acceptance in Europe. mAbs 2011;3:223-240.
7. European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies - nonclinical and clinical issues, May 2012. http://www.ema.europa. eu/docs/en_GB/document_library/Scientific_guideline/ 2012/06/WC500128686.pdf (accessed 11 Oct 2013).
8. European Medicines Agency. Guideline on the investigation of bioequivalence, January2010.http://www.ema.europa.eu/docs /en_GB/document_l ibrary/Scient i f ic_guidel i - ne/2010/01/WC500070039.pdf (accessed 11 Oct 2013).
9. Park W, Hrycaj P, Jeka S, et al. A randomised, double blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis Published Online First 16 May 2013. doi:10.1136/annrheumdis-2012-203091.
10. Yoo D, Hrycaj P, Miranda P, et al. randomised, double-blind, parallel- group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis Published Online First 16 May 2013. doi:10.1136/annrheumdis- 2012-203090.
11. Gu N, Yi S, Kim T, et al. Comparative Phamarcokinetics and Tolerability of Branded Etanercept (25 mg) and its biosimiliar (25 mg): a randomized, open-label, single-dose, two sequence, cross-over study in healthy Korean male volunteers. Clin Ther 2011;33:2029-2037.
12. Yi S, Kim S, Park M, et al. Comparative Pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel): a double-blind, single-dose, cross-over study in helathy volunteers. Biodrugs 2012;26:177-184.
13. Silva A, Kronthaler U, Koppenburg V, et al. Target-Directed Development And Preclinical Characterization Of The Proposed Biosimilar Rituximab Gp2013. Leuk Lymphoma Published Online First 11 Sept 2013. dOI 10.3109/10428194.2013.843090.
14. Korth-Bradley JM, Rubin AS, Hanna RK, et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000;34:161-164.
15. European Medicines Agency. EPAR summary for the public - Inflectra. http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Summary_for_the_public/human/002778/WC500151491.pdf (Accessed 11 Oct 2013).
16. European Medicines Agency. EPAR summary for the public - Remsima. http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Summary_for_the_public/human/002576/WC500150872.pdf (accessed 11 Oct 2013).
17. http://www.clinicaltrials.gov/ct2/show/NCT01709760? term=TuNEX&rank=1 (Accessed October 30, 2013)
18. http://www.clinicaltrials.gov/ct2/show/NCT01270997? term=HD203&rank=1 (Accessed October 30, 2013)
19. O'Connor A, Rogge M. Nonclinical development of a biosimilar: the current landscape. Bioanalysis 2013;5:537-544.
20. http://www.clinicaltrials.gov/ct2/show/NCT01274182? term=GP2013&rank=2 (Accessed October 30, 2013)
21. Chamberlain P. Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations. Bioanalysis 2013;5:561-574.